1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,215 | 0,235 | 27.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization | 109 | GlobeNewswire (Europe) | WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| Do | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus | 204 | GlobeNewswire (Europe) | WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc.") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding... ► Artikel lesen | |
| Mi | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 30.01. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.01. | Tevogen board to evaluate potential special cash dividend | 1 | Investing.com | ||
| 30.01. | Tevogen-Aufsichtsrat erwägt einmalige Sonderausschüttung | 4 | Investing.com Deutsch | ||
| 30.01. | Tevogen Bio Inc: Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders | 182 | GlobeNewswire (Europe) | WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate... ► Artikel lesen | |
| 29.01. | Tevogen Bio Inc: Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue | 339 | GlobeNewswire (Europe) | WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced that the current time- and individual performance-based long-term... ► Artikel lesen | |
| 12.01. | Tevogen Bio Inc: Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025 | 4 | GlobeNewswire (USA) | ||
| 22.12.25 | Tevogen Bio Inc: Tevogen CEO Donates Shares to Support Education for Underprivileged Children | 3 | GlobeNewswire (USA) | ||
| 19.12.25 | Tevogen Bio Inc: Tevogen CEO Donates Personal Shares to Support Local Fire Department | 3 | GlobeNewswire (USA) | ||
| 11.12.25 | Tevogen Bio Inc: Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock | 5 | GlobeNewswire (USA) | ||
| 09.12.25 | Tevogen Bio Inc: Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine | 1 | GlobeNewswire (USA) | ||
| 08.12.25 | Tevogen Bio Inc: Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook | 6 | GlobeNewswire (USA) | ||
| 14.11.25 | Tevogen Bio Inc: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q | 242 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended... ► Artikel lesen | |
| 14.11.25 | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Tevogen Bio Inc: Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID | 151 | GlobeNewswire (Europe) | This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk... ► Artikel lesen | |
| 03.11.25 | Tevogen Bio Inc: Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn | 159 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported... ► Artikel lesen | |
| 29.10.25 | Tevogen Bio Inc: Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress | 398 | GlobeNewswire (Europe) | WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore... ► Artikel lesen | |
| 15.10.25 | Tevogen Bio Inc: Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest | 398 | GlobeNewswire (Europe) | Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of... ► Artikel lesen |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | +1,38 % | Qiagen: Analysten sehen Wettbewerbssorgen als übertrieben | Nach Gesprächen mit dem Qiagen-Management auf Analysten-Konferenzen in den USA stufen Analysten die Aktie des Diagnostikspezialisten weiterhin positiv ein. Jefferies beließ es bei einer Kaufempfehlung... ► Artikel lesen | |
| AMGEN | 328,50 | -0,02 % | Is Amgen Stock Outperforming the Dow? | ||
| NOVAVAX | 8,495 | -0,97 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 20,010 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Advancing differentiated MC4R-based obesity programs into clinical development
Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 661,60 | 0,00 % | Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung | DJ Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung
Von Colin Kellaher
DOW JONES--Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,500 | -2,60 % | Is Inovio Pharmaceuticals Stock Going to $0? | ||
| COSCIENS BIOPHARMA | 1,560 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,88 | +1,23 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 53,62 | +0,15 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| XOMA ROYALTY | 22,200 | +1,83 % | Leerink raises Xoma stock price target on royalty outlook | ||
| PHIO PHARMACEUTICALS | 1,135 | +7,08 % | Quantum XChange treibt mit der neuesten Version von Phio TX einen EUCC-Meilenstein und die Skalierbarkeit für Unternehmen voran | Neuer EUCC-Compliance-Modus und bessere Hive-Architektur stärken die Sicherheit für regulierte europäische und globale Netzwerke Quantum XChange hat heute die neueste Version seiner Kryptografie-Managementplattform... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 0,848 | -4,69 % | Oragenics, Inc.: Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy | Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia... ► Artikel lesen | |
| INSMED | 125,00 | -1,57 % | INSMED INC - Jetzt springt der Funke über! | ||
| SWEDISH ORPHAN BIOVITRUM | 37,060 | +0,49 % | Sobi Targets SEK 55 Bln Revenue By 2030 | STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY) on Wednesday said it is hosting its Capital Markets Day, today, where the biopharma company plans to outline a new mid-term ambition... ► Artikel lesen |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,22 % bei einem Aktienkurs von 0,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.